REFERENCES
1. Osnabrugge RL, Mylotte D, Head SJ, et al. Aortic stenosis in the elderly: disease prevalence and number of candidates for transcatheter aortic valve replacement: a meta-analysis and modeling study. J Am Coll Cardiol 2013;62:1002-12.
2. Baumgartner H, Falk V, Bax JJ, et al. ESC Scientific Document Group. 2017 ESC/EACTS Guidelines for the management of valvular heart disease. Eur Heart J 2017;38:2739-91.
3. Nishimura RA, Otto CM, Bonow RO, et al. 2017 AHA/ACC focused update of the 2014 AHA/ACC guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol 2017;70:252-89.
4. Mack MJ, Leon MB, Thourani VH, et al. PARTNER 3 Investigators. Transcatheter aortic-valve replacement with a balloon-expandable valve in low-risk patients. N Engl J Med 2019;380:1695-705.
5. Popma JJ, Deeb GM, Yakubov SJ, et al. Evolut Low Risk Trial Investigators. Transcatheter aortic-valve replacement with a self-expanding valve in low-risk patients. N Engl J Med 2019;380:1706-15.
6. Durko AP, Osnabrugge RL, Van Mieghem NM, et al. Annual number of candidates for transcatheter aortic valve implantation per country: current estimates and future projections. Eur Heart J 2018;39:2635-42.
7. Vemulapalli S, Carroll JD, Mack MJ, et al. Procedural volume and outcomes for transcatheter aortic-valve replacement. N Engl J Med 2019;380:2541-50.
8. Lauck SB, Wood DA, Baumbusch J, et al. Vancouver transcatheter aortic valve replacement clinical pathway: minimalist approach, standardized care, and discharge criteria to reduce length of stay. Circ Cardiovasc Qual Outcomes 2016;9:312-21.
9. Wood DA, Lauck SB, Cairns JA, et al. The Vancouver 3M (Multidisciplinary, Multimodality, But Minimalist) Clinical pathway facilitates safe next-day discharge home at low-, medium-, and high-volume transfemoral transcatheter aortic valve replacement centers: The 3M TAVR Study. JACC Cardiovasc Interv 2019;12:459-69.
10. Barbanti M, van Mourik MS, Spence MS, et al. Optimising patient discharge management after transfemoral transcatheter aortic valve implantation: the multicentre European FAST-TAVI trial. EuroIntervention 2019;15:147-54.
11. Abdel-Wahab M, Mehilli J, Frerker C, et al. CHOICE investigators. Comparison of balloon-expandable vs self-expandable valves in patients undergoing transcatheter aortic valve replacement: the CHOICE randomized clinical trial. JAMA 2014;311:1503-14.
12. Toggweiler S, Nissen H, Mogensen B, et al. Very low pacemaker rate following ACURATE neo transcatheter heart valve implantation. EuroIntervention 2017;13:1273-80.
13. Kappetein AP, Head SJ, Généreux P, et al. Updated standardized endpoint definitions for transcatheter aortic valve implantation: the Valve Academic Research Consortium-2 consensus document. Eur Heart J 2012;33:2403-18.
14. Wayangankar SA, Elgendy IY, Xiang Q, et al. Length of stay after transfemoral transcatheter aortic valve replacement: an analysis of the Society of Thoracic Surgeons/American College of Cardiology Transcatheter Valve Therapy Registry. JACC Cardiovasc Interv 2019;12:422-30.
15. Dall'Ara G, Eltchaninoff H, Moat N, et al. Transcatheter Valve Treatment Sentinel Registry (TCVT) Investigators of the EurObservational Research Programme (EORP) of the European Society of Cardiology. Local and general anaesthesia do not influence outcome of transfemoral aortic valve implantation. Int J Cardiol 2014;177:448-54.
16. Ehret C, Rossaint R, Foldenauer AC, et al. Is local anaesthesia a favourable approach for transcatheter aortic valve implantation? BMJ Open 2017;7:e016321.
17. Saint S, Greene MT, Kowalski CP, Watson SR, Hofer TP, Krein SL. Preventing catheter-associated urinary tract infection in the United States: a national comparative study. JAMA Intern Med 2013;173:874-9.
18. Lansky AJ, Schofer J, Tchetche D, et al. A prospective randomized evaluation of the TriGuard™ HDH embolic DEFLECTion device during transcatheter aortic valve implantation: results from the DEFLECT III trial. Eur Heart J 2015;36:2070-8.
19. Nombela-Franco L, del Trigo M, Morrison-Polo G, et al. Incidence, causes, and predictors of early (≤30 days) and late unplanned hospital readmissions after transcatheter aortic valve replacement. JACC Cardiovasc Interv 2015;8:1748-57.
20. Kolte D, Khera S, Sardar MR, et al. Thirty-day readmissions after transcatheter aortic valve replacement in the United States: insights from the nationwide readmissions database. Circ Cardiovasc Interv 2017;10:e004472.
21. van der Boon RM, Nuis RJ, Benitez LM, et al. Frequency, determinants and prognostic implications of infectious complications after transcatheter aortic valve implantation. Am J Cardiol 2013;112:104-10.
22. Tirado-Conte G, Freitas-Ferraz AB, Nombela-Franco L, et al. Incidence, causes, and impact of in-hospital infections after transcatheter aortic valve implantation. Am J Cardiol 2016;118:403-9.
23. Ream K, Sandhu A, Valle J, et al. Ambulatory rhythm monitoring to detect late high-grade atrioventricular block following transcatheter aortic valve replacement. J Am Coll Cardiol 2019;73:2538-47.
